Under Priority Review status, the FDA has accepted Epizyme’s (NASDAQ:EPZM)
marketing application seeking approval of Tazverik (tazemetostat) for
the treatment of patients with relapsed/refractory follicular lymphoma
who have received at least two prior lines of systemic therapy.
The agency’s action date is June 18.
The FDA OK’d the methyltransferase inhibitor last month for epitheloid sarcoma.
https://seekingalpha.com/news/3542147-fda-accepts-epizymes-application-for-tazemetostat-for-follicular-lymphoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.